New Risk • Jun 01
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (₹301.0m market cap, or US$3.17m). Announcement • May 22
Deccan Health Care Limited to Report Q4, 2026 Results on May 30, 2026 Deccan Health Care Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 39% After last week's 39% share price gain to ₹10.46, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 64% over the past three years. New Risk • Mar 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹215.5m market cap, or US$2.30m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to ₹9.20, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 41x in the Personal Products industry in India. Total loss to shareholders of 65% over the past three years. Reported Earnings • Feb 15
Third quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.07 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.41 (up from ₹0.07 in 3Q 2025). Revenue: ₹173.9m (down 15% from 3Q 2025). Net income: ₹10.0m (up ₹8.58m from 3Q 2025). Profit margin: 5.8% (up from 0.7% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Feb 10
Deccan Health Care Limited to Report Q3, 2026 Results on Feb 13, 2026 Deccan Health Care Limited announced that they will report Q3, 2026 results on Feb 13, 2026 Announcement • Jan 12
Deccan Health Care Limited Announces Executive Changes Deccan Health Care Limited announced that Mr. Ronak Darji has tendered his resignation from the post of Company Secretary & Compliance Officer of the Company with immediate effect. The Company has accepted his resignation and relieved him from responsibilities with effect from close of business hours on December 1, 2025. Mr. Darji cited financial hardship due to non-payment of his October 2025 salary and pending November 2025 salary as reasons for his immediate resignation. The company noted that Mr. Darji did not follow internal grievance procedures to escalate his salary concerns, which should have been addressed through formal channels. The role of Company Secretary is classified as Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013, requiring adherence to professional conduct standards and accountability for compliance. Despite his resignation, Mr. Darji remains accountable for any compliance irregularities, fines, and penalties identified during his tenure. The company highlighted recent issues with delays in statutory filings and incomplete compliance submissions, attributing these lapses to Mr. Darji's performance. Mr. Darji's resignation was accepted subject to conditions, including the completion of exit formalities, handover of documents, and submission of compliance status reports. Further, the company has appointed Ms. Mohita Gupta, Chief Operating Officer (COO), as a designated compliance officer effective December 1, 2025. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹0.37 (vs ₹0.21 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.37 (up from ₹0.21 in 2Q 2025). Revenue: ₹214.0m (up 14% from 2Q 2025). Net income: ₹9.14m (up 73% from 2Q 2025). Profit margin: 4.3% (up from 2.8% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Nov 11
Deccan Health Care Limited to Report Q2, 2026 Results on Nov 14, 2025 Deccan Health Care Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹17.28, the stock trades at a trailing P/E ratio of 39.2x. Average trailing P/E is 54x in the Personal Products industry in India. Total loss to shareholders of 63% over the past three years. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹14.98, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 55x in the Personal Products industry in India. Total loss to shareholders of 63% over the past three years. Announcement • Sep 05
Deccan Health Care Limited, Annual General Meeting, Sep 30, 2025 Deccan Health Care Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2026 earnings released: EPS: ₹0.10 (vs ₹0.18 in 1Q 2025) First quarter 2026 results: EPS: ₹0.10 (down from ₹0.18 in 1Q 2025). Revenue: ₹221.5m (up 68% from 1Q 2025). Net income: ₹2.37m (down 35% from 1Q 2025). Profit margin: 1.1% (down from 2.7% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Aug 09
Deccan Health Care Limited to Report Q1, 2026 Results on Aug 14, 2025 Deccan Health Care Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Board Change • Jul 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Bhavika Sanghani was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • May 22
Deccan Health Care Limited to Report Fiscal Year 2025 Results on May 29, 2025 Deccan Health Care Limited announced that they will report fiscal year 2025 results at 12:15 PM, Indian Standard Time on May 29, 2025 Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹21.24, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 50x in the Personal Products industry in India. Total loss to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹19.64, the stock trades at a trailing P/E ratio of 34.4x. Average trailing P/E is 48x in the Personal Products industry in India. Total loss to shareholders of 47% over the past three years. New Risk • Mar 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Market cap is less than US$10m (₹472.9m market cap, or US$5.43m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Profit margins are more than 30% lower than last year (1.7% net profit margin). Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: ₹0.07 (vs ₹0.29 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.07 (down from ₹0.29 in 3Q 2024). Revenue: ₹204.3m (up 33% from 3Q 2024). Net income: ₹1.44m (down 73% from 3Q 2024). Profit margin: 0.7% (down from 3.4% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year. Announcement • Feb 10
Deccan Health Care Limited to Report Q4, 2025 Results on Feb 14, 2025 Deccan Health Care Limited announced that they will report Q4, 2025 results at 12:15 PM, Indian Standard Time on Feb 14, 2025 Announcement • Jan 02
Deccan Health Care Limited Announces Ramesh Kumar Steps Down from Non- Executive Independent Director Deccan Health Care Limited announced that Mr. Ramesh Kumar (DIN: 10480812) has stepped down from the position of the ‘Non- Executive Independent Director’ of the Company with effect from 31st December 2024 vide his resignation letter dated 31st December 2024. CEO of IFFCO-Tokio Insurance Services Limited. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹0.26 (vs ₹0.32 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.26 (down from ₹0.32 in 2Q 2024). Revenue: ₹188.2m (up 9.6% from 2Q 2024). Net income: ₹5.29m (down 2.2% from 2Q 2024). Profit margin: 2.8% (down from 3.1% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Nov 09
Deccan Health Care Limited to Report First Half, 2025 Results on Nov 14, 2024 Deccan Health Care Limited announced that they will report first half, 2025 results on Nov 14, 2024 Board Change • Sep 12
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Independent Director Ramesh Kumar was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 05
Deccan Health Care Limited, Annual General Meeting, Sep 27, 2024 Deccan Health Care Limited, Annual General Meeting, Sep 27, 2024, at 14:30 Indian Standard Time. Reported Earnings • Aug 01
First quarter 2025 earnings released: EPS: ₹0.18 (vs ₹0.18 in 1Q 2024) First quarter 2025 results: EPS: ₹0.18 (in line with 1Q 2024). Revenue: ₹131.9m (up 17% from 1Q 2024). Net income: ₹3.62m (up 21% from 1Q 2024). Profit margin: 2.7% (in line with 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Announcement • Jul 25
Deccan Health Care Limited to Report Q1, 2025 Results on Jul 31, 2024 Deccan Health Care Limited announced that they will report Q1, 2025 results on Jul 31, 2024 Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹27.00, the stock trades at a trailing P/E ratio of 36.9x. Average trailing P/E is 60x in the Personal Products industry in India. Total loss to shareholders of 12% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹0.80 (vs ₹0.22 in FY 2023) Full year 2024 results: EPS: ₹0.80 (up from ₹0.22 in FY 2023). Revenue: ₹597.4m (up 33% from FY 2023). Net income: ₹14.9m (up 310% from FY 2023). Profit margin: 2.5% (up from 0.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • May 24
Deccan Health Care Limited to Report Q4, 2024 Results on May 29, 2024 Deccan Health Care Limited announced that they will report Q4, 2024 results on May 29, 2024 Reported Earnings • Feb 07
Third quarter 2024 earnings released: EPS: ₹0.29 (vs ₹0.039 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹0.29 (up from ₹0.039 loss in 3Q 2023). Revenue: ₹153.4m (up 25% from 3Q 2023). Net income: ₹5.25m (up ₹5.92m from 3Q 2023). Profit margin: 3.4% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Announcement • Jan 30
Deccan Health Care Limited to Report Q3, 2024 Results on Feb 06, 2024 Deccan Health Care Limited announced that they will report Q3, 2024 results on Feb 06, 2024 Announcement • Nov 04
Deccan Health Care Limited to Report Q2, 2024 Results on Nov 11, 2023 Deccan Health Care Limited announced that they will report Q2, 2024 results on Nov 11, 2023 Announcement • Oct 13
Deccan Health Care Limited announced that it has received INR 140.2875 million in funding On October 12, 2023, Deccan Health Care Limited closed the transaction. The company issued 3,333,000 Equity Shares at an issue price of INR 30 per share (INR 20 premium) for the gross proceed of INR 99,990,000 and 5,373,000 Convertible Warrants at an issue price of INR 7.5 per warrant for the gross proceeds of INR 40,297,500; aggregate gross proceeds of INR 140,287,500. The transaction has been approved by the shareholders of the company. New Risk • Oct 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 77% per year over the past 5 years. Market cap is less than US$10m (₹757.8m market cap, or US$9.10m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings have declined by 77% per year over the past 5 years. Market cap is less than US$10m (₹583.6m market cap, or US$7.01m). Announcement • Sep 02
Deccan Health Care Limited, Annual General Meeting, Sep 27, 2023 Deccan Health Care Limited, Annual General Meeting, Sep 27, 2023, at 14:30 Indian Standard Time. New Risk • Aug 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 77% per year over the past 5 years. Market cap is less than US$10m (₹553.2m market cap, or US$6.69m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). Reported Earnings • Aug 16
First quarter 2024 earnings released: EPS: ₹0.18 (vs ₹0.15 in 1Q 2023) First quarter 2024 results: EPS: ₹0.18 (up from ₹0.15 in 1Q 2023). Revenue: ₹112.4m (up 9.6% from 1Q 2023). Net income: ₹2.99m (up 20% from 1Q 2023). Profit margin: 2.7% (up from 2.4% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Aug 08
Deccan Health Care Limited to Report Q1, 2024 Results on Aug 14, 2023 Deccan Health Care Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 04
Full year 2023 earnings released: EPS: ₹0.22 (vs ₹0.20 in FY 2022) Full year 2023 results: EPS: ₹0.22 (up from ₹0.20 in FY 2022). Revenue: ₹450.4m (up 36% from FY 2022). Net income: ₹3.64m (up 13% from FY 2022). Profit margin: 0.8% (down from 1.0% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • May 19
Deccan Health Care Limited to Report Second Half, 2023 Results on May 30, 2023 Deccan Health Care Limited announced that they will report second half, 2023 results on May 30, 2023 Board Change • Dec 02
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Additional Director Kandlakunta Samhitha was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 30
Deccan Health Care Limited Announces Resignation of Mr. Hitesh Patel as Non-Executive Director Deccan Health Care Limited announced that Mr. Hitesh Patel, Non-executive Director has resigned due to his personal reasons, effective from close of business hours of 28th November, 2022. Reported Earnings • Nov 19
First half 2023 earnings released: EPS: ₹0.30 (vs ₹0.71 in 1H 2022) First half 2023 results: EPS: ₹0.30 (down from ₹0.71 in 1H 2022). Revenue: ₹205.2m (up 9.5% from 1H 2022). Net income: ₹4.98m (down 56% from 1H 2022). Profit margin: 2.4% (down from 6.0% in 1H 2022). Announcement • Nov 06
Deccan Health Care Limited to Report Q2, 2023 Results on Nov 14, 2022 Deccan Health Care Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Reported Earnings • Sep 10
Full year 2022 earnings released: EPS: ₹0.20 (vs ₹0.25 in FY 2021) Full year 2022 results: EPS: ₹0.20 (down from ₹0.25 in FY 2021). Revenue: ₹331.7m (down 1.8% from FY 2021). Net income: ₹3.23m (down 17% from FY 2021). Profit margin: 1.0% (down from 1.2% in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 04
Full year 2022 earnings released: EPS: ₹0.21 (vs ₹0.25 in FY 2021) Full year 2022 results: EPS: ₹0.21 (down from ₹0.25 in FY 2021). Revenue: ₹333.9m (down 1.1% from FY 2021). Net income: ₹3.23m (down 17% from FY 2021). Profit margin: 1.0% (down from 1.2% in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Announcement • May 25
Deccan Health Care Limited to Report Second Half, 2022 Results on May 30, 2022 Deccan Health Care Limited announced that they will report second half, 2022 results on May 30, 2022 Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improved over the past week After last week's 30% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 43x in the Personal Products industry in India. Total loss to shareholders of 67% over the past three years. Executive Departure • Aug 05
Independent Director Savita Bhutani has left the company On the 28th of July, Savita Bhutani's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under Savita's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.75 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Jul 15
Full year 2021 earnings released: EPS ₹0.25 (vs ₹6.42 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹337.8m (down 20% from FY 2020). Net income: ₹3.90m (down 96% from FY 2020). Profit margin: 1.2% (down from 24% in FY 2020). The decrease in margin was primarily driven by lower revenue. Is New 90 Day High Low • Feb 04
New 90-day low: ₹24.00 The company is down 29% from its price of ₹33.65 on 05 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₹26.25 The company is down 26% from its price of ₹35.70 on 20 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. Reported Earnings • Jan 06
First half 2021 earnings released: ₹4.13 loss per share The company reported a poor first half result with weaker earnings, revenues and control over expenses. First half 2021 results: Revenue: ₹104.8m (down 52% from 1H 2020). Net loss: ₹64.9m (down 227% from profit in 1H 2020). Announcement • Dec 30
Deccan Health Care Limited to Report First Half, 2021 Results on Jan 04, 2021 Deccan Health Care Limited announced that they will report first half, 2021 results on Jan 04, 2021 Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improved over the past week After last week's 24% share price gain to ₹36.25, the stock is trading at a trailing P/E ratio of 5.6x, up from the previous P/E ratio of 4.6x. This compares to an average P/E of 46x in the Personal Products industry in India. Total return to shareholders over the past year is a loss of 54%. Is New 90 Day High Low • Dec 04
New 90-day low: ₹29.30 The company is down 32% from its price of ₹42.95 on 04 September 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period. Is New 90 Day High Low • Oct 28
New 90-day low: ₹33.00 The company is down 12% from its price of ₹37.30 on 30 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period. Is New 90 Day High Low • Sep 30
New 90-day low: ₹33.20 The company is down 13% from its price of ₹38.00 on 02 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period. Announcement • Sep 26
Deccan Health Care Limited Announces Board Appointments Deccan Health Care Limited at its board meeting held on September 24, 2020 board members appointed Ruchi Khattar as an Additional Director (Non- Executive, Independent) and Ms. Kandlakunta Samhitha as an Additional Director (Non-Executive, Independent) of the Company. Ruchi Khattar was associated as a senior member in Max Bupa Health Insurance Company Limited and Max Life Insurance Company Limited. She has 25 years Of experience in Accounts, Finance and insurance Compliances etc. Kandlakunta Samhitha as a Member of the Beta Gamma Sigma, the international honorary society for AACSB accredited business schools and Member of the Sigma Zeta Chapter, Sigma Iota Epsilon National Honorary Management. Announcement • Jul 26
Deccan Health Care Limited to Report Q4, 2020 Final Results on Jul 31, 2020 Deccan Health Care Limited announced that they will report Q4, 2020 final results on Jul 31, 2020 